The relationship between cardiac hemodynamics and exercise tolerance in cystic fibrosis

Heart and Lung: Journal of Acute and Critical Care

Volumn 45, Issue 3, 2016, Pages 283-290

  Van Iterson, Erik H ^a,b   Wheatley, Courtney M ^a,c   Baker, Sarah E ^a,c   Morgan, Wayne J ^d   Snyder, Eric M ^b,c  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Cardiac output; Cardiopulmonary exercise test; CFTR; Exercise capacity; Functional limitation; Pulmonary function; Stroke volume

Indexed keywords

ACETYLENE; CARBON DIOXIDE; OXYGEN;

ARTICLE; BICYCLE ERGOMETER; BREATHING; CARDIOPULMONARY EXERCISE TEST; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; EXERCISE; EXERCISE DURATION; EXERCISE TOLERANCE; FEMALE; FORCED EXPIRATORY VOLUME; HEART HEMODYNAMICS; HEART INDEX; HUMAN; MALE; OXYGEN CONSUMPTION; PRIORITY JOURNAL; WORKLOAD; ADULT; EXERCISE TEST; HEMODYNAMICS; LUNG FUNCTION TEST; PATHOPHYSIOLOGY; PHYSIOLOGY; YOUNG ADULT;

ADULT; CYSTIC FIBROSIS; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HEMODYNAMICS; HUMANS; MALE; OXYGEN CONSUMPTION; RESPIRATORY FUNCTION TESTS; YOUNG ADULT;

EID: 84961875122     PISSN: 01479563     EISSN: 15273288     Source Type: Journal    
DOI: 10.1016/j.hrtlng.2016.03.001     Document Type: Article

References (53)

1. MacKenzie T., Gifford A.H., Sabadosa K.A., et al. Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation patient registry. Ann Intern Med 2014, 161:233-241.
2. Stephenson A.L., Tom M., Berthiaume Y., et al. A contemporary survival analysis of individuals with cystic fibrosis: a cohort study. Eur Respir J 2015, 45:670-679.
3. Dalemans W., Barbry P., Champigny G., et al. Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation. Nature 1991, 354:526-528.
4. Kerem E., Viviani L., Zolin A., et al. Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registry. Eur Respir J 2014, 43:125-133. Group EPRS.
5. Moorcroft A.J., Dodd M.E., Webb A.K. Exercise testing and prognosis in adult cystic fibrosis. Thorax 1997, 52:291-293.
6. Nixon P.A., Orenstein D.M., Kelsey S.F., Doershuk C.F. The prognostic value of exercise testing in patients with cystic fibrosis. N Engl J Med 1992, 327:1785-1788.
7. Martin C., Chapron J., Hubert D., et al. Prognostic value of six minute walk test in cystic fibrosis adults. Respir Med 2013, 107:1881-1887.
8. Lands L.C., Heigenhauser G.J., Jones N.L. Analysis of factors limiting maximal exercise performance in cystic fibrosis. Clin Sci 1992, 83:391-397.
9. Leroy S., Perez T., Neviere R., Aguilaniu B., Wallaert B. Determinants of dyspnea and alveolar hypoventilation during exercise in cystic fibrosis: impact of inspiratory muscle endurance. J Cyst Fibros 2011, 10:159-165.
10. Pastre J., Prevotat A., Tardif C., Langlois C., Duhamel A., Wallaert B. Determinants of exercise capacity in cystic fibrosis patients with mild-to-moderate lung disease. BMC Pulm Med 2014, 14:74.
11. Troosters T., Langer D., Vrijsen B., et al. Skeletal muscle weakness, exercise tolerance and physical activity in adults with cystic fibrosis. Eur Respir J 2009, 33:99-106.
12. Dunnink M.A., Doeleman W.R., Trappenburg J.C., de Vries W.R. Respiratory muscle strength in stable adolescent and adult patients with cystic fibrosis. J Cyst Fibros 2009, 8:31-36.
13. Godfrey S., Mearns M. Pulmonary function and response to exercise in cystic fibrosis. Arch Dis Child 1971, 46:144-151.
14. Wheatley C.M., Foxx-Lupo W.T., Cassuto N.A., et al. Impaired lung diffusing capacity for nitric oxide and alveolar-capillary membrane conductance results in oxygen desaturation during exercise in patients with cystic fibrosis. J Cyst Fibros 2011, 10:45-53.
15. Sellers Z.M., De Arcangelis V., Xiang Y., Best P.M. Cardiomyocytes with disrupted CFTR function require CaMKII and Ca2+-activated Cl- channel activity to maintain contraction rate. J Physiol 2010, 588:2417-2429.
16. Sellers Z.M., Naren A.P., Xiang Y., Best P.M. MRP4 and CFTR in the regulation of cAMP and beta-adrenergic contraction in cardiac myocytes. Eur J Pharmacol 2012, 681:80-87.
17. Solbach T.F., Paulus B., Weyand M., Eschenhagen T., Zolk O., Fromm M.F. ATP-binding cassette transporters in human heart failure. Naunyn Schmiedebergs Arch Pharmacol 2008, 377:231-243.
18. Sellers Z.M., McGlocklin L., Brasch A. Strain rate echocardiography uncovers subclinical left ventricular dysfunction in cystic fibrosis. J Cyst Fibros 2015, 14:654-660.
19. Van Iterson E.H., Karpen S.R., Baker S.E., Wheatley C.M., Morgan W.J., Snyder E.M. Impaired cardiac and peripheral hemodynamic responses to inhaled beta2-agonist in cystic fibrosis. Respir Res 2015, 16:103.
20. Koelling T.M., Dec G.W., Ginns L.C., Semigran M.J. Left ventricular diastolic function in patients with advanced cystic fibrosis. Chest 2003, 123:1488-1494.
21. Lands L.C., Heigenhauser G.J., Jones N.L. Cardiac output determination during progressive exercise in cystic fibrosis. Chest 1992, 102:1118-1123.
22. Ionescu A.A., Ionescu A.-A., Payne N., Obieta-Fresnedo I., Fraser A.G., Shale D.J. Subclinical right ventricular dysfunction in cystic fibrosis. Am J Respir Crit Care Med 2012, 163:1212-1218.
23. Ozcelik N., Shell R., Holtzlander M., Cua C. Decreased right ventricular function in healthy pediatric cystic fibrosis patients versus non-cystic fibrosis patients. Pediatr Cardiol 2013, 34:159-164.
24. Sellers Z.M., Kovacs A., Weinheimer C.J., Best P.M. Left ventricular and aortic dysfunction in cystic fibrosis mice. J Cyst Fibros 2013, 12:517-524.
25. Cohen-Cymberknoh M., Shoseyov D., Kerem E. Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life. Am J Respir Crit Care Med 2011, 183:1463-1471.
26. Lloyd-Jones D.M., Larson M.G., Leip E.P., et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2002, 106:3068-3072. Framingham Heart S.
27. Lloyd-Jones D.M., Larson M.G., Beiser A., Levy D. Lifetime risk of developing coronary heart disease. Lancet 1999, 353:89-92.
28. Newman A.B., Simonsick E.M., Naydeck B.L., et al. Association of long-distance corridor walk performance with mortality, cardiovascular disease, mobility limitation, and disability. JAMA 2006, 295:2018-2026.
29. Weber K.T., Janicki J.S. Cardiopulmonary exercise testing for evaluation of chronic cardiac failure. Am J Cardiol 1985, 55:22A-31A.
30. ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003, 167:211-277. American Thoracic S and American College of Chest P.
31. Rowntree R.K., Harris A. The phenotypic consequences of CFTR mutations. Ann Hum Genet 2003, 67:471-485.
32. Farrell P.M., Rosenstein B.J., White T.B., et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: cystic Fibrosis Foundation consensus report. J Pediatr 2008, 153:S4-S14.
33. Hansen J.E., Sue D.Y., Wasserman K. Predicted values for clinical exercise testing. Am Rev Respir Dis 1984, 129:S49-S55.
34. Cohen J. A power primer. Psychol Bull 1992, 112:155.
35. ATS/ERS Task Force: standardisation of lung function testing. Eur Respir J 2005, 26:319-338. Society AT.
36. Hulzebos H., Werkman M., Van Brussel M., Takken T. Towards an individualized protocol for workload increments in cardiopulmonary exercise testing in children and adolescents with cystic fibrosis. J Cyst Fibros 2012, 11:550-554.
37. Coleman K.J., Ngor E., Reynolds K., et al. Initial validation of an exercise "vital sign" in electronic medical records. Med Sci Sports Exerc 2012, 44:2071-2076.
38. de Simone G., Devereux R.B., Daniels S.R., et al. Stroke volume and cardiac output in normotensive children and adults. Assessment of relations with body size and impact of overweight. Circulation 1997, 95:1837-1843.
39. Sinaasappel M., Stern M., Littlewood J., et al. Nutrition in patients with cystic fibrosis: a European Consensus. J Cyst Fibros 2002, 1:51-75.
40. Saur J., Trinkmann F., Doesch C., et al. The impact of pulmonary disease on noninvasive measurement of cardiac output by the inert gas rebreathing method. Lung 2010, 188:433-440.
41. Cander L. Solubility of inert gases in human lung tissue. J Appl Physiol 1959, 14:538-540.
42. Snyder E.M., Johnson B.D., Beck K.C. An open-circuit method for determining lung diffusing capacity during exercise: comparison to rebreathe. J Appl Physiol (1985) 2005, 99:1985-1991.
43. Triebwasser J.H., Johnson R.L., Burpo R.P., Campbell J.C., Reardon W.C., Blomqvist C.G. Noninvasive determination of cardiac output by a modified acetylene rebreathing procedure utilizing mass spectrometer measurements. Aviat Space Environ Med 1977, 48:203-209.
44. Hoeper M.M., Maier R., Tongers J., et al. Determination of cardiac output by the Fick method, thermodilution, and acetylene rebreathing in pulmonary hypertension. Am J Respir Crit Care Med 1999, 160:535-541.
45. Perel A., Wesselink W., Settels J. The Nexfin monitor-a totally non-invasive cardiac output monitor. Anaesthesia, Pharmacology, Intensive Care and Emergency Medicine APICE 2011, 103-108. Springer.
46. Agostoni P., Cattadori G., Apostolo A., et al. Noninvasive measurement of cardiac output during exercise by inert gas rebreathing technique: a new tool for heart failure evaluation. J Am Coll Cardiol 2005, 46:1779-1781.
47. Van Iterson E.H., Baker S.E., Wheatley C.M., Morgan W.J., Snyder E.M. The capacity for gas transfer within lungs does not influence the relationship between oxygen uptake and cardiac hemodynamics during exercise in cystic fibrosis patients. Paper Presented at: American Thoracic Society 2015, Denver.
48. Stöhr E.J., McDonnell B., Thompson J., et al. Left ventricular mechanics in humans with high aerobic fitness: adaptation independent of structural remodelling, arterial haemodynamics and heart rate. J Physiol 2012, 590:2107-2119.
49. Stewart G.M., Yamada A., Kavanagh J.J., Haseler L.J., Chan J., Sabapathy S. Reproducibility of echocardiograph-derived multilevel left ventricular apical twist mechanics. Echocardiography 2015, 33:257-263.
50. Balmain B., Stewart G., Yamada A., Chan J., Haseler L., Sabapathy S. The impact of an experimentally induced increase in arterial blood pressure on left ventricular twist mechanics. Exp Physiol 2016, 101:124-134.
51. Mutlak D., Aronson D., Lessick J., Reisner S.A., Dabbah S., Agmon Y. Functional tricuspid regurgitation in patients with pulmonary hypertension: is pulmonary artery pressure the only determinant of regurgitation severity?. Chest 2009, 135:115-121.
52. Dhutia N.M., Zolgharni M., Willson K., et al. Guidance for accurate and consistent tissue Doppler velocity measurement: comparison of echocardiographic methods using a simple vendor-independent method for local validation. Eur Heart J Cardiovasc Imaging 2014, 15:817-827.
53. Marwick T.H., Nemec J.J., Pashkow F.J., Stewart W.J., Salcedo E.E. Accuracy and limitations of exercise echocardiography in a routine clinical setting. J Am Coll Cardiol 1992, 19:74-81.